|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
15.96 USD |
-2.21% | +3.97% | +29.65% | |
Published on 05/24/2025 at 04:37
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12 |
04:37am |
RE |
|
Mineralys Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04:35 PM |
May. 20 |
|
|
Mineralys Announces Late-Breaking Presentation Of Phase 3 Launch-HTN Trial |
May. 20 |
RE |
|
Mineralys Therapeutics Q1 GAAP Loss Widens |
May. 12 |
MT |
|
Mineralys Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 |
May. 12 |
|
|
Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 12 |
CI |
|
Certain Pre-funded Warrants of Mineralys Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2025. |
May. 10 |
CI |
|
Certain Stock Options of Mineralys Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2025. |
May. 10 |
CI |
|
Certain Common Stock of Mineralys Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-MAY-2025. |
May. 10 |
CI |
|
Mineralys Therapeutics, Inc. Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine |
Apr. 23 |
CI |
|
Mineralys Therapeutics Insider Sold Shares Worth $879,008, According to a Recent SEC Filing |
Apr. 03 |
MT |
|
Mineralys Therapeutics, Inc. – Special Call |
Apr. 01 |
|
|
Mineralys Therapeutics, Inc. Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) |
Mar. 29 |
CI |
|
Mineralys Therapeutics Insider Bought Shares Worth $8,100,000, According to a Recent SEC Filing |
Mar. 18 |
MT |
|
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday |
Mar. 12 |
MT |
|
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of Key Inflation Report |
Mar. 12 |
MT |
|
Mineralys Therapeutics Prices $175 Million Share Offering |
Mar. 12 |
MT |
|
Mineralys Therapeutics Announces Pricing Of $175.0 Million Underwritten Public Offering Of Common Stock |
Mar. 11 |
RE |
|
Mineralys Therapeutics Launches $250 Million Public Offering of Shares |
Mar. 10 |
MT |
|
Sector Update: Health Care Stocks Decline Late Afternoon |
Mar. 10 |
MT |
|
Sector Update: Health Care |
Mar. 10 |
MT |
|
Top Midday Gainers |
Mar. 10 |
MT |
|
Mineralys’ drug for persistent hypertension succeeds in two trials |
Mar. 10 |
RE |
|
Analyst recommendations: Ford, Tesla, ServiceNow, Rio Tinto, FedEx… |
Mar. 10 |
 |
|
Mineralys Therapeutics Says Lorundrostat Met Trial Endpoints for Treating Hypertension; Shares Up Pre-Bell |
Mar. 10 |
MT |
MLYS: Dynamic Chart
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
More about the company
Buy
Average target price
39.29USD
Spread / Average Target
+146.15%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
